Vector-producing tumor-tracking multipotent mesenchymal stromal cells for suicide cancer gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Cancer Research

Background:

• Suicide gene therapy using retroviral vector-producing cells has shown marginal benefits as an adjuvant to glioblastoma resection.
• Inefficient delivery of vectors and transgenes to tumor cells limits the efficacy of current approaches.

Purpose of the Study:

• To explore the potential of mesenchymal stromal cells (MSCs) as effective delivery vehicles for retroviral vectors in cancer gene therapy.
• To investigate the feasibility of transducing tumors with recombinant progeny vectors delivered by MSCs for treating diffuse cancers like glioblastoma.

Main Methods:

• Previous studies demonstrated that adenovirus-retrovirus hybrid vectors can engineer tumor cells to produce retroviral progeny that destroy satellite tumor cells.
• The current strategy proposes using multipotent mesenchymal stromal cells (MSCs) to deliver retroviral vectors.

Main Results:

• MSCs have shown an ability to home to tumor cells in vivo and deliver therapeutic gene or immune products with minimal host rejection.
• This approach has the potential to improve the outcomes of suicide gene therapy for aggressive and diffuse tumors.

Conclusions:

• While the strategy of using MSCs for retroviral vector delivery in suicide gene therapy requires further testing in various tumor models, it holds significant promise.
• This method could particularly benefit diffuse cancers such as glioblastoma multiforme, potentially improving treatment outcomes.